Barclays (LON:BARC) initiated coverage on PolyPeptide Group AG (SIX:PPGN:SW) stock with an Overweight rating and a price target of CHF 40.00. The firm anticipates a return to positive EBITDA for ...

Barclays analyst Emily Field initiated coverage with a Buy rating on PolyPeptide Group AG (PPGN – Research Report) today and set a price target ...

This new collaboration provides a scalable, integrated solution for developing and manufacturing complex peptide drugs efficiently.

Juan José González, CEO of PolyPeptide: “The large-scale capacity expansion in Malmö allows us to further deepen the long-standing collaboration with an important GLP-1 customer. We are making good ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Epstein, R. H., Bolle, A., Steinberg, C. M., Kellenberger, E., Boy de la Tour, E., Chevalley, R., Edgar, R. S., Susman, M., Denhardt, G. H., and Lielausis, A., Cold ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of ...